Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3247030 | 0.81 | SLC22A1 (0.48) | DNM1TSHR | |
| Hydrochloric Acid SCHEMBL3245992 | 0.80 | DNM1 (0.33) | DNM1 | |
| Hydrochloric Acid SCHEMBL3238829 | 0.80 | — | — | |
| SCHEMBL17022990 | 0.78 | SLC22A1 (0.50) | DNM1TSHR | |
| SCHEMBL12852722 | 0.77 | — | — | |
| SCHEMBL12852749 | 0.77 | DNM1 (0.34) | DNM1 | |
| Hydrochloric Acid SCHEMBL1995337 | 0.76 | APEX1 (0.33) | — | |
| SCHEMBL12375259 | 0.73 | MEN1 (0.30) | KDM4EPMP22TSHRNFKB1 | |
| SCHEMBL17030355 | 0.71 | DNM1 (0.38) | DNM1 | |
| Hydrochloric Acid SCHEMBL3248335 | 0.71 | DNM1 (0.45) | DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100272783-A1 | Methods of Treating Infections of the Nail | NOVABAY PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | claimed |
| WO-2010124237-A1 | METHODS OF TREATING INFECTIONS OF THE NAIL | NOVABAY PHARMACEUTICALS INC. (US) | 2010-10-28 | — | — | WO | claimed |
| WO-2010124237-A1 | METHODS OF TREATING INFECTIONS OF THE NAIL | NOVABAY PHARMACEUTICALS INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100272783-A1 | Methods of Treating Infections of the Nail | NOVABAY PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272783-A1 | Methods of Treating Infections of the Nail | POLR1C, TYR, NACA | KDM4E 3839/4885PMP22 2145/4885ATM 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.